355P EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study
2024 · Annals of Oncology · 2 citations
https://doi.org/10.1016/j.annonc.2024.08.303